Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging

Peter Marckmann, Lone Skov, Kristian Rossen, Anders Dupont, Mette Brimnes Damholt, James Goya Heaf, Henrik S. Thomsen

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Abstrakt

    Nephrogenic systemic fibrosis is a new, rare disease of unknown cause that affects patients with renal failure. Single cases led to the suspicion of a causative role of gadodiamide that is used for magnetic resonance imaging. This study therefore reviewed all of the authors' confirmed cases of nephrogenic systemic fibrosis (n = 13) with respect to clinical characteristics, gadodiamide exposure, and subsequent clinical course. It was found that all had been exposed to gadodiamide before the development of nephrogenic systemic fibrosis. The delay from exposure to first sign of the disease was 2 to 75 d (median 25 d). Odds ratio for acquiring the disease when gadodiamide exposed was 32.5 (95% confidence interval 1.9 to 549.2; P < 0.0001). Seven (54%) patients became severely disabled, and one died 21 mo after exposure. No other exposure/event than gadodiamide that was common to more than a minority of the patients could be identified. These findings indicate that gadodiamide plays a causative role in nephrogenic systemic fibrosis.

    OriginalsprogEngelsk
    Sider (fra-til)2359-2362
    Antal sider4
    TidsskriftJournal of the American Society of Nephrology
    Vol/bind17
    Udgave nummer9
    DOI
    StatusUdgivet - 1 sep. 2006

    Fingeraftryk Udforsk hvilke forskningsemner 'Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging' indeholder.

    Citationsformater